EXACT Sciences Corporation

379 articles with EXACT Sciences Corporation

• 

  Certified Great Places to Work By BioSpace Hotbed Regions

  7/18/2019

  Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...

• Exact Sciences Designated a Great Place to Work-Certified™ Company in 2019

  7/17/2019

  Hundreds of open positions offer opportunity to join growing company

• Exact Sciences to host annual meeting, second-quarter 2019 results webcasts and calls

  7/9/2019

  Exact Sciences Corp. announced that the company will host webcasts and conference calls of its annual stockholders meeting and its second-quarter 2019 financial results.

• Exact Sciences Advances Fight Against Colorectal Cancer With Opening Of New Laboratory

  6/26/2019

  Company's total lab processing capacity expected to reach 7 million by end of year

• Exact Sciences to participate in June investor conferences - May 31, 2019

  5/31/2019

  Exact Sciences Corp. announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.

• Exact Sciences Advances Pipeline Capabilities with Mayo Clinic

  5/20/2019

  Early data on pancreatic cancer detection presented at Digestive Disease Week® 2019

• Exact Sciences Presents New Data Reinforcing Performance of Cologuard®

  5/17/2019

  Researchers to Present Real-World Findings at Digestive Disease Week® 2019

• Exact Sciences to participate in May investor conferences

  5/1/2019

  Exact Sciences Corp. announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.

• First-quarter revenue and Cologuard test volume increased 79 percent to $162 million and 334,000, respectively

  4/30/2019

  Estimated Cologuard market share increased to 4.6 percent during the first quarter

• Exact Sciences schedules first-quarter 2019 earnings call

  4/8/2019

  Exact Sciences Corp. announced that the company plans to release its first-quarter 2019 financial results after the close of the U.S. financial markets on Apr. 30, 2019.

• Kathleen Sebelius Appointed to Exact Sciences Board

  3/19/2019

  Former Health and Human Services Secretary brings government and health care expertise to company working to detect cancer earlier

• Exact Sciences Announces Upsizing and Pricing of 0.3750% Convertible Senior Notes Due 2027

  3/6/2019

  Exact Sciences Corporation announced today that it has priced its underwritten public offering of 0.3750% convertible senior notes due 2027 (the "Notes") and upsized the offering from $600 million to $650 million aggregate principal amount.

• Exact Sciences Announces Offering of $600 Million Convertible Senior Notes Due 2027

  3/5/2019

  Exact Sciences Corporation announced an underwritten public offering of $600 million aggregate principal amount of convertible senior notes due 2027 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission on Form S-3.

• Exact Sciences to participate in March investor conferences

  3/1/2019

  Exact Sciences Corp. announced that company management will be presenting at the following investor conferences and invited investors to participate by webcast.

• Cologuard Helps Screen Two Million People for Colorectal Cancer

  2/27/2019

  Exact Sciences Announces Milestone Ahead of Cologuard Classic, National Colorectal Cancer Awareness Month

• Total 2018 revenue increased 71 percent to $454 million, and 934,000 people were screened with Cologuard

  2/21/2019

  Nearly 15,000 healthcare providers ordered their first Cologuard test during the fourth quarter, and approximately 147,000 have ordered since the test was launched

• 2019 Cologuard Classic Ups the Ante with New 'Hole-In-One Attendance Challenge' to Drive Awareness of Colorectal Cancer and Importance of Early Detection

  2/21/2019

  Potential donations totaling $1.5 million would benefit colorectal cancer research and Tucson youth athletics

• Exact Sciences schedules fourth-quarter, full-year 2018 earnings call

  2/4/2019

  Exact Sciences Corp. announced that the company plans to release its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Feb. 21, 2019.

• Exact Sciences to report $454-455M in total revenue, 71-percent growth for 2018

  1/7/2019

  Cologuard test volume increased 64 percent, with approximately 934,000 tests completed in 2018

• Exact Sciences to participate in 37th J.P. Morgan Healthcare Conference

  12/20/2018

  Exact Sciences Corp. today announced that company management will be presenting at the following investor conference and invited investors to participate by webcast.